INTRODUCTION {#SEC1}
============

Toxin--antitoxin (TA) modules are small autoregulated operons found in bacteria and archaea ([@B1],[@B2]). They are involved in several physiological functions, most notably in plasmid stabilization ([@B3]), in bacterial stress-response ([@B4],[@B5]) and in the transition to the persister state ([@B6]). Most abundant are type II modules, which consist of two genes: one encoding for a toxin protein and the other for a corresponding antitoxin protein. The toxins shutdown bacterial metabolism by interfering with the components of the translation machinery or with the DNA replication and transcription systems (reviewed in [@B4],[@B6]). In normal growing cells, the activity of the toxin is controlled by tight binding of the antitoxin. Activation of the toxins depends on the degradation of the antitoxin by intracellular proteases such as Lon and is triggered by various stress stimuli, such as nutrient deprivation and antibiotic treatment or in the case of plasmid-residing TA modules plasmid loss ([@B7]).

Most prevalent among TA toxins are ribonucleases. MazF and HicA toxins mostly cleave free mRNA ([@B8],[@B9]) while ribonucleases from the RelE superfamily cleave mRNAs in a ribosome-dependent context ([@B10]). tRNAs are also the target of several different types of toxins ([@B11]). The RelE superfamily can be divided into several subfamilies based on sequence identities of the toxins. Different members of the RelE family have historically been given different names such as HigB, MqsR, BrnT, YafQ and YoeB, but the nomenclature does not always coincides well with sequence relationships between the toxins. The structures of different members of the RelE family are known in their free, ribosome-bound and antitoxin-bound states. Despite differences in active site residues, all of them bind to the A site of the translating ribosome ([@B12]--[@B14]). Some toxins are inhibited by the antitoxin that covers the active site ([@B15],[@B16]) yet notable exceptions include MqsA, PvHigB and YafQ, where the antitoxin does not interact with the active site ([@B17]--[@B20]).

The *higBA* module was first discovered on plasmid Rts1 from *Proteus vulgaris* ([@B21]). It has an unusual, inverted toxin-before-antitoxin gene organization that was later also observed in some other TA modules such as *mqsRA, hicAB* and *brnTA* ([@B9],[@B22],[@B23]). The crystal structure of the Rts1 plasmid-born *higBA* from *P. vulgaris* (from now on referred to as Pv*higBA*) shows a toxin with a RelE-type ribonuclease fold and an unusual antitoxin that is fully structured, with a single domain harboring both the toxin neutralizing and DNA binding activities ([@B13],[@B17]).

Chromosomal counterparts of the *higBA* module were identified on the *Vibrio cholerae* chromosome II, which hosts two such modules *higBA1* and *higBA2*. The activation of these two orthologs depends on the Lon protease and is triggered by amino acid starvation ([@B24],[@B25]). The *V. cholerae* HigB2 toxin (*Vc*HigB2) is a ribosome-dependent RNase that cleaves translating mRNA molecules with a similar cleavage pattern as *Escherichia coli* RelE ([@B24],[@B26]). These genes were initially annotated as *higBA* homologs given their reverse gene organization. However, sequence alignments indicate that the active site residues are more similar to RelE and considering these *higBA* homologs display a similar cleavage pattern as RelE, it is assumed they function as RelE homologs.

In this work, we present the crystal structures of the *Vc*HigBA2 complex and its components *Vc*HigB2 and *Vc*HigA2 together with thermodynamics of their mutual interactions and the structure-activity relationship of the toxin\'s active site. Our results show that there are important differences between *Vibrio* and *Proteus* encoded *higBA* modules concerning the structures of toxin and antitoxin as well as the neutralization mechanism. The structures of free and antitoxin-bound *Vc*HigB2 toxin are related by a shift in the register of a β-strand, resulting in two conformations of the catalytically important Arg64. We discuss this β-strand sliding, which is observed for the first time for a ribonuclease protein, in the context of toxin neutralization.

MATERIALS AND METHODS {#SEC2}
=====================

Production of *Vc*HigBA2, *Vc*HigB2, *Vc*HigA2 and *Vc*HigA2ΔN {#SEC2-1}
--------------------------------------------------------------

Peptides (*Vc*HigA2~3-22~ and *Vc*HigA2~3-33~) were obtained from China Peptides Co., Ltd. and were at least 95% pure according to the manufacturer. Both peptides contain an additional tryptophan residue at their C-terminus to enable concentration determination by UV spectrophotometry. Cloning of the *V. cholerae higBA2* operon and purification of the *Vc*HigBA2 complex as well as of the individual *Vc*HigA2 and *Vc*HigB2 proteins have been described previously ([@B27],[@B28]). A sequence corresponding to the truncated version of *Vc*HigA2 containing C-terminal domain only (residues 37--104) was cloned by a commercial supplier (GenScript) into the pET21b+ vector (Novagen) using its NdeI and XhoI restriction sites. In this construct an un-cleavable Histidine tag is placed at the C-terminus of *Vc*HigA2ΔN and protein was produced following the same protocol as for the production of *Vc*HigBA2 ([@B27],[@B28]).

Selenomethionine-labeled *Vc*HigBA2 complex was produced using auxotrophic *E. coli* B834 (DE3) cells. A preculture was grown at 37°C in SelenoMet medium (Molecular Dimensions Limited) supplemented with ampicillin (100 mg l^−1^), L-methionine (50 mg l^−1^) and 0.2% glucose. After overnight incubation the cells were pelleted, washed with sterile water and used to inoculate the main culture in the same medium as before but with L-Se-methionine (50 mg l^−1^) added. Cells grown for 10 h at 37°C (OD~600\ nm~∼1) were induced with 1 mM IPTG and incubated overnight. From this point on the complex was purified according to the same protocol as the unlabeled complex ([@B27]).

The concentrations of the proteins and peptides were determined by measuring UV absorption using extinction coefficients for proteins calculated according to Pace *et al.* ([@B29]). The following molar extinction coefficients at 280 nm were used (in M^−1^ cm^−1^): 42860 (*Vc*HigBA2 complex, 2:2 stoichiometry), 15930 (*Vc*HigB2), 11000 (full-length and truncated *Vc*HigA2 dimer), 5500 (*Vc*HigA2~3-22~ and *Vc*HigA2~3-33~).

Nanobody production {#SEC2-2}
-------------------

Nanobodies were raised against *Vc*HigB2 via the VIB Nanobody Service Facility (<http://www.vib.be/en/research/services/Nanobody-Service-Facility>). The nanobody gene sequences were re-cloned into to the pHEN6c expression vector, which was subsequently transformed into *E. coli* WC6 cells. Cell cultures were grown in TB medium supplemented with ampicillin (100 mg l^−1^) at 37°C with aeration. The cultures were grown until OD~600\ nm~ reached 0.8, after which the temperature was lowered to 28°C. Expression was induced by adding 1 mM IPTG and the cultures were incubated overnight. Cells were harvested by centrifugation and resuspended in 0.2 M TRIS--HCl, 0.5 M sucrose, 0.65 mM ethylenediaminetetraacetic acid (EDTA), PH 8.0. The nanobodies were extracted from the periplasm by osmotic shock by resuspending cells followed by 45 min incubation at 4°C with stirring at 200 rpm. The lysate was centrifuged (40 min at 25 000 *g*) to remove the cell debris and loaded onto a Ni-NTA column equilibrated in 50 mM phosphate pH 7.0, 1 M NaCl buffer. The column was washed with five column volumes of 50 mM phosphate pH 6.0, 1 M NaCl buffer to elute the non-specifically bound proteins. The nanobodies were eluted with 50 mM phosphate pH 4.5, 1 M NaCl. The nanobody-containing fractions were pooled and neutralized by the addition of 1 M TRIS--HCl pH 7.4. The pooled fractions were further purified on a Superdex 75 HR 10/30 gel-filtration column run with 20 mM TRIS-HCl pH 8.0, 150 mM NaCl elution buffer. The purity of the nanobody samples was analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).

*In vitro* activity assay {#SEC2-3}
-------------------------

The activity of *Vc*HigB2 and its neutralization by *Vc*HigA2 and the *Vc*HigA2-derived peptides was analyzed by measuring the synthesis of the reporter protein eGFP using the *in vitro* synthesis kit (PURExpress, New England Biolabs). The reactions (12.5 μl) were set up according to the manufacturers' instructions and supplemented with 75 ng of purified PCF fragment (purified using Wizard® SV Gel and PCR Clean-Up System, Promega) coding for the eGFP reporter protein (amplified from pPROBE\'-GFP plasmid with primers 5΄: GCGAATTAATACGACTCACTATAGGGCT--TAAGTATAAGGAGGAAAAAATATGAGTAAAGGAGAAGAACTTTTCAC and 3΄: AAACCCCTCCGT--TTAGAGAGGGGTTATGCTAGTTATTATTTTTCGAACTGCGGGTGGCTCCATTTGTATAGTTCATC--CATGCCA. Reactions were incubated for 3 h at 37°C in absence and presence of varying amounts of *Vc*HigB2 and its variants, *Vc*HigA2, *Vc*HigA2~3-22~ and *Vc*HigA2~3-33~. Relative amount of synthesized protein was determined through fluorescence measurement by diluting the sample to 60 μl and using 483 and 535 nm as excitation and emission wavelengths. Concentration of WT toxin or toxin variant required for half-maximal inhibition of reporter protein synthesis was obtained by fitting the inhibition curve, which was the average of three experiments, to the logistic function ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}).

*In vitro* ribosome binding assay {#SEC2-4}
---------------------------------

Ribosomes from *E. coli* MRE600 strain were purified on 10--50% sucrose gradient in buffer containing 20 mM HEPES-KOH pH 7.5, 4 mM β-mercaptoethanol, 10 mM MgCl~2~, 150 mM NH~4~Cl as previously described ([@B30]). Ribosomes were collected top to bottom and the profiles were measured based on absorption at 280 nm. Ribosomal fractions were pooled and sucrose was removed using buffer exchange by Amicon 100K filters (Millipore). We used T7 polymerase to synthesize mRNA (5΄-GGGCAAAACAAAAGGAGGCTAAATATGTTCTAGCAAAACAAAACAAAA-GAATT-3΄) and tRNAs were extracted from *E. coli* XL1-Blue cells as previously described ([@B31]). The ribosome binding assays were performed in 10 mM HEPES pH 7.5, 70 mM NH~4~Cl, 30 mM KCl, 4 mM MgCl~2~, 1 mM DTT. Ribosomes were used at a final concentration of 2 μM and were incubated with 2-fold excess of mRNA for 5 min at 37°C and 4-fold excess of tRNA for 30 min prior to the assays. *Vc*HigB2 toxin was added in 5-fold excess and incubated for 20 min. All the reactions were layered on the sucrose gradient and free *Vc*HigB2 toxin was also layered on the sucrose gradient as control. Fractions corresponding to proteins and to ribosomal fractions were pooled and TCA precipitated, pellets were washed two times with acetone, air dried and re-suspended in SDS-loading buffer. Protein and ribosomal fractions were then analysed by SDS-PAGE and western blot with antibodies against polyHis tag.

Crystallography {#SEC2-5}
---------------

Crystallization and data collection for *Vc*HigBA2, *Vc*HigA2 and *Vc*HigB2 have been described ([@B27]). Complexes of *Vc*HigB2 with nanobodies Nb2, Nb6 and Nb8 were prepared by mixing 1 mg of toxin with 1.3 mg of nanobody and isolating the pure complex by size-exclusion chromatography using the BioRad Enrich 70-10-30 column. Isolated complexes were crystallized using the hanging drop method. Drops consisting of 1 μl of protein solution (10 mg ml^−1^ in 200 mM NaCl, 20 mM TRIS--HCl pH 8.0) and 1 μl of precipitant solution were equilibrated against 110 μl precipitant solution. Various commercial screens were used: Crystal Screen and Crystal Screen 2 (Hampton Research), Morpheus, PACT premier and ProPlex (Molecular Dimensions) and Jena Classic (Jena Bioscience). All final crystallization conditions are listed in Table S1.

All data were measured at the SOLEIL synchrotron (Gif-sur-Yvette, France) at 100K on beamline PROXIMA1 using a PILATUS 6M detector. All data were indexed, integrated and scaled with XDS ([@B32]). The structure of the *Vc*HigBA2 complex was determined using SAD phasing. Se-Met sites were located using SHELXD using the selenium anomalous signal ([@B33]) and phases were calculated using PHASER-EP ([@B34]). Following density improvement with PARROT ([@B35]), an initial model was automatically build with BUCCANEER ([@B36]). The latter was used as a starting point for iterative refinement with phenix.refine ([@B37]) and manual rebuilding using Coot ([@B38]).

All other structures were solved by molecular replacement using PHASER-MR ([@B34]) and using the C-terminal domain of the *Vc*HigA2 antitoxin or the *Vc*HigB2 toxin as present in the *Vc*HigBA2 complex as search models. To locate nanobodies, the co-ordinates of a nanobody against β-lactamase BcII and stripped of its complementarity-determining region (CDR) loops ([@B39]), (PDB ID: 3DWT) was used as search model. In all cases, the structures were manually rebuilt using Coot and refined using phenix.refine. The final refinement cycles included TLS refinement (one TLS group per chain). Data collection and refinement statistics are given in [Table S1](#sup1){ref-type="supplementary-material"}.

Small angle X-ray scattering {#SEC2-6}
----------------------------

SAXS data were collected at 15°C in HPLC mode at the SWING beamline at the SOLEIL synchrotron (Gif-sur-Yvette, France). The *Vc*HigA2 sample (8 mg/ml in 20 mM TRIS--HCl pH 8.0 and 200 mM NaCl) was injected into a Shodex KW 402.5-4F column and ran at 0.2 ml/min. The data frames (1 ms exposure) were interrupted by a dead time of 0.5 ms. The buffer scatter was measured at the beginning of the chromatogram (during the dead volume), while the sample scatter was collected during the peak elution, which enables the acquisition of data at different protein concentrations. The data were processed with Foxtrot ([@B40]) and the ATSAS package ([@B41]). After buffer subtraction, Guinier analysis was performed on each curve using the program AUTORG ([@B41]). The curves of sufficient quality and stable R~g~ value along the elution peak were merged into a single final scatter curve used in further analysis. The molecular weights of the proteins and the protein complexes was estimated by using the Q~R~ ratio derived from the invariant volume of correlation ([@B42]).

A model of the *Vc*HigA2 conformational ensemble was generated using the Ensemble Optimization Method (EOM) ([@B43]). An initial pool of 10 000 random conformations was generated for the disordered N-terminal segment (residues 2--37) attached to the folded C-terminal domain based on the following assumptions: (i) the Cα distribution of the disordered segment is one found in random-coils, (ii) the symmetry of the folded core dimer is C~2~ (iii) no overall structure symmetry is imposed. A final ensemble was selected from the pool of conformations with the EOM algorithm based on the experimental scattering curve and this process was repeated five times. These final ensembles had χ^2^ values of 5.9, 1.1, 1.2, 1.2, 1.2 and consisted of 5--7 models. Based on the R~G~ and D~MAX~ values of the individual models all ensembles (except the first one) are structurally similar. The model ensemble with the lowest χ^2^ value (1.1) is considered to best represent the true ensemble and structural parameters of each model in this model ensemble are given in [Supplementary Table S4](#sup1){ref-type="supplementary-material"}. The quality of the model ensemble was assessed using the R~SAS~ and χ^2^~FREE~ parameters as proposed recently ([@B42]) and is reported in [Supplementary Table S3](#sup1){ref-type="supplementary-material"}.

CD spectroscopy {#SEC2-7}
---------------

Circular dichroism (CD) measurements were carried out at 25°C on an Aviv 62A DS CD spectrophotometer (Aviv Associates, NJ, USA) in a cuvette with 1 mm optical path length. All data were measured in 20 mM phosphate pH 7.0, 150 mM NaCl buffer in the wavelength range of 190--250 nm using a spectral bandwidth of 0.5 nm and an averaging time of 2 s. For measurements of the induction of secondary structure in the antitoxin *Vc*HigA2 upon *Vc*HigB2 binding, spectra of free *Vc*HigB2 (14 μM), free *Vc*HigA2 (6 μM) and of the *Vc*HigBA2 TA complex (14 μM toxin mixed with 6 μM antitoxin dimer) were measured. The spectrum of *Vc*HigA2 in its bound conformation was estimated as difference spectrum between the spectrum of the *Vc*HigBA2 complex and the spectrum of free *Vc*HigB2 toxin. To estimate the CD spectrum of the antitoxin N-terminal domain of *Vc*HigA2 in its native unbound state, the spectrum of the truncated antitoxin variant consisting of the C-terminal domain only (*Vc*HigA2ΔN) was subtracted from the spectrum of the full-length antitoxin (both protein were at 20 μM concentration). The CD spectrum of the *Vc*HigA2~3-33~ peptide derived from the *Vc*HigA2 N-terminal domain was measured at 12 μM. The reported mean molar ellipticities (in degrees cm^2^ dmol^−1^) were obtained from the raw data (ellipticities) by taking into account the molar concentration (*c*) and the optical path length (*l*) through the relation \[*θ*\] = *θ* /(*c l*).

Isothermal titration calorimetry {#SEC2-8}
--------------------------------

Samples were dialyzed against 20 mM sodium phosphate buffer pH 7.5, 150 mM sodium chloride, 1 mM EDTA and filtered. Prior to the experiments the samples were degassed for 20 min. All experiments were performed in a VP-ITC micro-calorimeter (MicroCal, CT, USA). The concentration of *Vc*HigB2 in the cell was 1 μM and the concentration of the macromolecule in the syringe (*Vc*HigA2 or *Vc*HigA2~3-22~) depended on the desired final stoichiometry. Raw data were integrated using the MicroCal Origin software to obtain the enthalpy change (per mole of ligand added per injection) as a function toxin/antitoxin ratio *r* at temperature *T*. The enthalpy changes accompanying complex formation were obtained by correcting the measured enthalpies for the dilution effects (in case of strong binding, the dilution enthalpy was estimated using the measured enthalpy changes above stoichiometric ratios).

Calorimetric curves were measured at four different temperatures (15, 25, 37, 42°C) that are below the temperatures that induce unfolding of the protein samples. For the analysis of the titration curves (enthalpy change Δ*H*(*T,r*) measured at different molar ratios *r*), a model function was derived based on binding models assuming two equivalent independent binding sites on the *Vc*HigA2 or one binding site on the *Vc*HigA2 peptides:$$\documentclass[12pt]{minimal}
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}{}$\bar{\nu }$\end{document}$ is the average number of occupied binding sites), which contains information on the site binding constant *K* was derived from the corresponding mass-balance equations and expressed in an analytical form. The model function is defined at any *r* and *T* by the enthalpy Δ*H*~b~*°(T~0~)* and free energy Δ*G*~b~*°(T~0~) (* = -*RT~0~*·ln*K(T~0~)*) of binding (*T~0~* = reference temperature = 25°C) and heat capacity of binding Δ*c*°*~p,b~* (assumed to be temperature-independent quantity) ([@B30]). Values of parameters Δ*H*~b~*°(T~0~)*, Δ*G*~b~*°(T~0~) and* Δ*c°~p,b~* were determined using the global fitting approach based on Levenberg--Marquardt least-square minimization of the discrepancy between the model function and experimental titration curves measured at different *T*. Validity of the fitted parameters was assessed using a Monte-Carlo error propagation analysis ([Supplementary Figure S6](#sup1){ref-type="supplementary-material"}).

Structure-based thermodynamic calculations {#SEC2-9}
------------------------------------------

Polar (A~P~) and nonpolar (A~N~) contributions of the solvent accessible surface were calculated using NACESS 2.1 with the default set of parameters ([@B44]). Change of the solvent accessible surface due to the formation of the *Vc*HigBA2 was calculated by subtracting total surface of the proteins in the unbound state from that of the *Vc*HigBA2 complex. The heat capacity change was estimated by the relation introduced by Murphy and Freire ([@B45]).

RESULTS {#SEC3}
=======

Crystal structure of *Vc*HigB2 {#SEC3-1}
------------------------------

As *Vc*HigB2 resisted crystallization by conventional methods we used *Vc*HigB2-specific cameloid single-chain antibody fragments as crystallization chaperones. From the blood of a single llama immunized with *Vc*HigB2, a library was constructed that was panned for *Vc*HigB2 binders using phage display. From this library, 10 unique nanobody sequences were obtained, of which five were used to produce protein (selection was based on good expression yields). From these five nanobodies, three (Nb2, Nb6 and Nb8) eventually gave crystals of sufficient quality for structure determination. In these three complexes nanobodies are bound to different *Vc*HigB2 epitopes and the resulting structures of the *Vc*HigB2 are very similar---with 0.7 Å (*Vc*HigB2-Nb6 versus Nb8) and 1.4 Å (*Vc*HigB2 Nb2 versus Nb6) rmsd for 94 out of 110 Cα atoms ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). This suggest that nanobody binding does not significantly disturb the fold of the protein, and that the conformation of *Vc*HigB2 observed in these crystals may be a good approximation to that of the toxin in the unbound state.

The *Vc*HigB2 toxin consists of a four-stranded antiparallel β-sheet core flanked by two N-terminal α-helices (helices α1 and α2) on one side and a longer C-terminal α-helix (helix α3) on the other side (Figure [1A](#F1){ref-type="fig"}). This architecture is typical for a large family of microbial RNases that includes other TA related mRNA interferases such as RelE, MqsR, YoeB and YafQ ([@B15],[@B18]--[@B20],[@B46]). Electron density is seen for the entire molecule except for the affinity tag and residues Ala53-Ser63 of loop β2-β3, which has a disorder-promoting sequence ASKGKGRGGS (dashed line in Figure [1A](#F1){ref-type="fig"}).

![The structure and activity of *Vc*HigB2 toxin. (**A**) Left: the structure of the *Vc*HigB2 toxin. Secondary structure elements and positively charged β2-β3 loop, which is missing from the model are indicated. Active site residues are shown as blue sticks. Right: detailed view of the active site residues, which coordinate two sulphate ions from the crystallization mixture (yellow). The mRNA (gray) as found in the *Ec*RelE-ribosome structure (PDB ID: 4V7J) is superimposed for comparison. The side chain of Lys84 lacks clear electron density, but is modeled here in a likely position and shown as dashed stick. (**B**) Comparison of the active site of the *Vc*HigB2 (red) and the *Ec*RelE (green, PDB ID: 3KHA). *Vc*HigB2 residues (blue sticks) that correspond to the active site residues of *Ec*RelE (green sticks) are shown. (**C**) Concentrations of WT toxin and its variants to achieve half-maximal inhibition of the reporter protein synthesis in the *in vitro* activity assay.](gkx138fig1){#F1}

A DALI search identified *E. coli* RelE (*Ec*RelE, PDB 3KHA, DALI score 9.6, ([@B47])) as the closest structural relative of *Vc*HigB2. Although *Vc*HigB2 and *Ec*RelE share only 17% sequence identity, their tertiary structures are well preserved (2.5 Å rmsd for 82 of 94 Cα atoms). Notable differences are observed for the packing of the C-terminal helix against the β-sheet core and for loop β2-β3, which is structured and significantly shorter in *Ec*RelE (Figure [1B](#F1){ref-type="fig"}). Apart from *Ec*RelE, *Vc*HigB2 shares high structural similarity with RelJ, YoeB, YafQ, the archeal RelEs (which are all ribonucleases,([@B15],[@B19],[@B46]) and also with *Caulobacter crescentus* ParE and *E. coli* O157 ParE2 ([@B48],[@B49]), which have different biochemical activities ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}, sequence identities and DALI scores are given in [Supplementary Table S2](#sup1){ref-type="supplementary-material"}). Surprisingly, plasmid-born *Pv*HigB, together with BrnT from *Brucella abortus* and MqsR from *E. coli* belongs to the more distant relatives ([Supplementary Figure S2 and Table S2](#sup1){ref-type="supplementary-material"}, ([@B17],[@B18])). While the β-sheet core is still preserved, these toxins completely lack the C-terminal helix α3 and also differ in the arrangement and number of N-terminal helices.

*Vc*HigB2 has a RelE-like active site {#SEC3-2}
-------------------------------------

Similar to *Ec*RelE ([@B24],[@B26]), the ribosome bound *Vc*HigB2 toxin cleaves translating mRNA molecules after the second codon position without a strong sequence preference. The active site of *Vc*HigB2 is located on the β-sheet surface and is almost identical to the active site of *Ec*RelE (Figure [1B](#F1){ref-type="fig"}). The active site surface is positively charged, suggesting strong electrostatic interactions with the negatively charged mRNA phosphate backbone. Two sulphate ions are located in the active site of *Vc*HigB2, strongly resembling the positions of backbone phosphates of the mRNA molecule in the RelE-ribosome structure (Figure [1A](#F1){ref-type="fig"}, ([@B12])). It is not uncommon for ribonucleases to harbor a sulphate or phosphate ion in their active site cleft in absence of a substrate, and has been observed for other RelE family members such as YafQ ([@B20]).

Based on the sequence alignment and structural similarity with *Ec*RelE (sequence alignment is shown in [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}) we prepared several variants of *Vc*HigB2 with alanine substitutions of the presumed active site residues (Arg51, Arg64, Tyr82 and Lys84). For all of these toxin variants orders of magnitude higher concentrations are needed to inhibit synthesis of a reporter protein in our *in vitro* translation assay compared to the WT toxin (Figure [1C](#F1){ref-type="fig"} and [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). Most disruptive is the substitution of Lys84 leading to a 3000-fold drop in toxin activity, followed by Tyr82 with a 1200-fold reduction (Figure [1C](#F1){ref-type="fig"}). Substitutions of Arg51 and Arg64 on strands β2 and β3, which coordinate a sulphate ion in our structure, were less disruptive (170- and 350-fold reduction relative to WT). Similar to *Ec*RelE, the active site of *Vc*HigB2 toxin lacks a His-Glu or His-His acid-base pair as is commonly found in RNases and other members of the RelE superfamily. Recent data on the cleavage mechanism of *Ec*RelE points toward a model where the acid-base pair consists of an arginine (Arg81) and a lysine (Lys54) residue ([@B50],[@B51]). Interestingly, in *Vc*HigB2 this arginine is structurally replaced by Lys84 while the lysine is replaced by Arg51. We also tested a toxin variant where the positively charged flexible β2-β3 loop (residues 54--63) is substituted by a sequence of three alanines. This modification reduces the activity by 120-fold relative to the WT enzyme (Figure [1C](#F1){ref-type="fig"}).

*Vc*HigA2 contains of a helix-turn-helix DNA binding/dimerization motif {#SEC3-3}
-----------------------------------------------------------------------

The *Vc*HigA2 antitoxin counteracts the *Vc*HigB2 toxin and rescues growth-stalled bacterial cells ([@B24]). The molecular weight estimate for *Vc*HigA2 from SAXS is in accordance with previous estimates from analytical gel-filtration experiments, which indicates that this antitoxin is a dimer ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}, ([@B28])). Crystals of the C-terminal domain of *Vc*HigA2 (residues 38--104) were obtained after a 4-month waiting period from trials utilizing the full length protein ([@B27]). These crystals contain in their asymmetric unit four dimers of the C-terminal domain arranged around a non-crystallographic four-fold axis while the N-terminal domain is absent due to degradation as shown before ([@B27]).

The *Vc*HigA2 C-terminal domain is a Lambda repressor-like DNA binding domain. The domain has a small hydrophobic core surrounded by five α-helices (Figure [2A](#F2){ref-type="fig"}). The dimerization interface is formed by helices α4 and α5, while helices α2 and α3 form a characteristic HTH motif that likely binds the operator DNA. This arrangement differs dramatically from the *Pv*HigA where the dimerization interface is formed by a longer helix α5. This results in an overall distinct relative orientation of the two monomers in the dimer, and thus a different relative disposition of the two DNA binding motifs ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}, ([@B17])). Taken together the DNA-binding domain of the *Vc*HigA is more similar to the MqsA antitoxin (PDB ID: 3GN5, ([@B18])), while that of *Pv*HigA antitoxin seems to belong to a distinct group of HTH proteins that also includes HigA from *E. Coli* (PDB 2ICT) and *Coxiella brunetii* (PDB ID: 3TRB).

![*Vc*HigA2 antitoxin has two domains. (**A**) Crystal structure of the *Vc*HigA2 C-terminal DNA-binding domain. Two monomers are in different colors. Helix-turn-helix motif is indicated on one monomer. (**B**) CD spectra of the full-length *Vc*HigA2 (orange) and the N-terminal truncate *Vc*HigA2ΔN (red) have very similar intensities indicating that the N-terminus is unstructured. The difference spectrum (*Vc*HigA2-*Vc*HigA2ΔN) corresponding to the N-terminal domain in the full-length antitoxin (gray) has features typical of random coil and is very similar to the that of the N-terminal peptide *Vc*HigA23-33 (blue). Intensities for blue and gray spectra are given on the right y-axis. (**C**) The measured SAXS curve of the full-length antitoxin (orange) is superimposed on the calculated scatter of the EOM-derived model (blue). The extended, folded conformation of the *Vc*HigA2 as observed in the *Vc*HigBA2 complex is not compatible with the SAXS data (yellow). Inset: the normalized Kratky plot is in agreement with the presence of a globular domain combined with a flexible segment. (**D**) The representative EOM-derived model of the full-length antitoxin consists of seven conformations of the N-terminal domain (in different colors).](gkx138fig2){#F2}

The N-terminal region of *Vc*HigA2 is intrinsically disordered {#SEC3-4}
--------------------------------------------------------------

Several lines of evidence suggest that the *Vc*HigA2 N-terminal region (residues 1--36), which was not observed in the crystal structure of the free antitoxin, is intrinsically disordered in solution. The CD spectrum of a peptide encompassing residues Asn3 to Asn33 is typical for a random coil polypeptide with a minimum below 200 nm and a very weak ellipticity above 210 nm (blue curve, Figure [2B](#F2){ref-type="fig"}). The CD spectrum of the N-terminal region in its native state (attached to the C-terminal domain) was estimated by calculating the difference spectrum between full length *Vc*HigA2 and a truncate (*Vc*HigA2ΔN) consisting of amino acid residues 37--104. The latter protein, which mirrors the residues seen in the crystal structure, is thermodynamically stable and shows a CD spectrum with essentially the same α-helical content as the full length protein (Figure [2B](#F2){ref-type="fig"}). The difference spectrum is similar to the spectrum of the isolated peptide and suggests presence of the random coil structure (gray and blue curves, Figure [2B](#F2){ref-type="fig"}).

Further evidence for an N-terminal intrinsically disordered domain comes from SAXS experiments. The normalized Kratky plot of *Vc*HigA2 shows a bell-shaped curve (typical for a globular macromolecule), followed by a continuous increase of the intensity at higher scattering angles (a sign of flexibility) (Figure [2C](#F2){ref-type="fig"}, inset). Such a shape is characteristic for a protein consisting of a globular domain connected to an IDP domain ([@B52]). Together with the CD data, this thus agrees with a model in which the *Vc*HigA2 antitoxin has a well-structured dimeric C-terminal domain, as seen in the crystal structure, and ∼36 amino acids long disordered N-terminal segment.

Based on these assumptions we applied the Ensemble Optimization Method ([@B43]) to derive a model for the structural ensemble of the full-length antitoxin. The minimal ensemble model that satisfactorily describes the data includes seven conformations (Figure [2C](#F2){ref-type="fig"} and [D](#F2){ref-type="fig"}, model statistics are given in [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Interestingly, these conformations belong to two structural groups. One contains extended conformations of the N-terminal domain, while the other is characterized by more compact conformations. The structural parameters for all conformations of the representative ensemble are given in [Supplementary Table S4](#sup1){ref-type="supplementary-material"}.

The N-terminal domain of *Vc*HigA2 inhibits *Vc*HigB2 through folding upon binding {#SEC3-5}
----------------------------------------------------------------------------------

Increasing amounts of *Vc*HigB2 abolish synthesis of the reporter protein in an *in vitro* translation assay and half-maximal inhibition is observed at 5 nM concentration of *Vc*HigB2 toxin ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}, ([@B28])). Addition of *Vc*HigA2 in stoichiometric amounts inactivates *Vc*HigB2 (Figure [3A](#F3){ref-type="fig"}). Interestingly, peptides derived from the *Vc*HigA2 N-terminus also counteract the activity of the toxin (Figure [3A](#F3){ref-type="fig"}). The minimal element for toxin inhibition is the *Vc*HigA2 peptide encompassing residues Asn3-Glu22, which corresponds to the segment that folds into an α-helix upon toxin binding (see below). Using an *in vitro* ribosome binding assay we also observe that the *Vc*HigA2~3-22~ peptide prevents *Vc*HigB2 binding to the ribosomes (Figure [3B](#F3){ref-type="fig"}). Thus the intrinsically disordered N-terminal domain is sufficient for *Vc*HigB2 toxin regulation.

![Inhibition of the *Vc*HigB2 toxin by the *Vc*HigA2 antitoxin. (**A**) Fluorescent reporter protein is synthesized in the *in vitro* translation assay and addition of *Vc*HigB2 toxin (at 50 nM, 10 times above its IC50) inhibits its synthesis. Addition of BSA (at 1 μM) has no effect on toxin activity, while peptides derived from the N-terminus of *Vc*HigA2 antitoxin (*Vc*HigA2~3-22~ and *Vc*HigA2~3-33~) as well as full-length antitoxin inhibit toxin activity. Concentration of *Vc*HigB2 toxin was constant 50 nM. Fluorescence of the reporter protein (eGFP) was normalized using the values for the positive (no toxin) and negative controls (no eGFP coding fragment). (**B**) Top: ribosome profiles from ultracentrifugation on a sucrose gradient. Bottom: anti-his western blot of the protein and ribosomal fractions show that *Vc*HigA2~3-22~ prevents binding of the *Vc*HigB2 toxin to the ribosome. (**C**) Binding to the toxin is coupled by the folding of the antitoxin. CD spectrum of the bound antitoxin estimated as the difference spectrum between *Vc*HigBA2 complex and *Vc*HigB2. (**D**) Calorimetric titrations of toxin into antitoxin performed at different temperatures. Global fits of the model function (Equation [1](#M1){ref-type="disp-formula"}) to the data measured at different temperatures are shown as solid lines.](gkx138fig3){#F3}

The interaction between *Vc*HigA2 and *Vc*HigB2 is characterized by a very high affinity and by structuring of the antitoxin N-terminal domain. Coupled folding and binding is evident from the comparison of the CD spectra from free and the *Vc*HigB2-bound *Vc*HigA2 (Figure [3C](#F3){ref-type="fig"}). The interaction was studied using ITC and the corresponding thermodynamic parameters were obtained by global fitting of the model function (Equation [1](#M1){ref-type="disp-formula"}) to the titration curves measured at four different temperatures (see Methods). This procedure ensures that the parameters Δ*G*~b~°, Δ*H*~b~°, *T*Δ*S*~b~° and Δ*c°~p,b~* are reliable within the error margins as determined from the Monte Carlo error propagation analysis (Figure [3D](#F3){ref-type="fig"} and [Supplementary Figure S6](#sup1){ref-type="supplementary-material"}). The dissociation constant of the *Vc*HigB2--*Vc*HigA2 complex is 50 pM (at 25°C; Δ*G*~b~° = −14.1 ± 0.5 kcal mol^−1^). Binding is driven by a high negative enthalpy change (Δ*H*~b~° = −26.6 ± 0.9 kcal mol^−1^) and is opposed by an unfavorable entropy contribution (*T*Δ*S*~b~° = **−**12.5 ± 1.0 kcal mol^−1^). Similar thermodynamic characteristics were observed also for high-affinity binding of the intrinsically disordered CcdA antitoxin domain to the toxin CcdB from *ccdAB* TA module ([@B53]). The negative enthalpy change likely originates from the folding of the N-terminal domain (in particular the formation of an α-helix) and from specific interactions between *Vc*HigB2 and *Vc*HigA2. The unfavorable entropic contributions likely originate from the reduction of rotational and translational degrees of freedom due to the association of *Vc*HigB2 and *Vc*HigA2 molecules and from the reduction of conformational degrees of freedom due to the folding of the N-terminal domain of *Vc*HigA2. Moreover, the binding is associated with a decrease of the heat capacity. The obtained experimental value of −0.95 kcal mol^−1^ K^−1^ is in agreement with the corresponding heat capacity change estimated on the basis of changes of the accessible surface areas (−1.05 ± 0.08 kcal mol^−1^ K^−1^) ([@B45]) and suggests that the binding is accompanied by a favorable desolvation entropy contribution.

Structure of the heterotetrameric *Vc*HigBA2 complex {#SEC3-6}
----------------------------------------------------

Crystals of the *Vc*HigBA2 complex contain a *Vc*HigA2 dimer of which the extended N-termini fold and wrap around *Vc*HigB2 to form an elongated HigB2-HigA2-HigA2-HigB2 heterotetramer (Figure [4A](#F4){ref-type="fig"}). The electron density is clear and continuous except for the affinity tags and again the positively charged β2-β3 loop of *Vc*HigB2. The N-terminal region of *Vc*HigA2 folds into an N-terminal α-helix (residues 3--22) followed by a short β-strand (residues 28--37). This β-strand is added to the β-sheet core of *Vc*HigB2 while the α-helix binds along the β-sheet surface. The structure of the N-terminal segment of *Vc*HigA2 does not possess a hydrophobic core on its own, in agreement with our observations that in solution and in absence of *Vc*HigB2, this segment remains unfolded.

![Structure of the heterotetrameric *Vc*HigBA2 complex. (**A**) Overall structure of the complex. The two *Vc*HigB2 toxins are in red, the two chains of the antitoxin dimer are in gray and blue. (**B**) Interactions between the toxin and the antitoxin\'s N-terminal domain. The electrostatic surface of the *Vc*HigB2 toxin was calculated with ABPS using default parameters ([@B60]). (**C**) Conformational changes in the *Vc*HigB2 induced by binding to *Vc*HigA2. The antitoxin N-terminal helix (blue) partially displaces the *Vc*HigB2 C-terminal helix (toxin in its free state is shown in gold, toxin in the bound state in red) and shifts the register of the β-strand β3 (green). The two positions of the catalytically important Arg64 are shown in sticks.](gkx138fig4){#F4}

The interaction between *Vc*HigA2 and *Vc*HigB2 buries a total of 5300 Å^2^ of solvent accessible surface, most of which is accounted for by the binding of the antitoxin N-terminal helix. Nonpolar residues along one side of the *Vc*HigA2 N-terminal helix are facing the β-sheet surface of *Vc*HigB2, thereby creating an extended hydrophobic core (Figure [4B](#F4){ref-type="fig"}). On the opposite side of the *Vc*HigA2 N-terminal helix several charged residues tighten the binding via electrostatic interactions (Figure [4B](#F4){ref-type="fig"}). In addition to the interactions with the N-terminal domain of *Vc*HigA2, there is an additional binding interface employing the globular domain of *Vc*HigA2. This involves positioning of the *Vc*HigB2 α2 helix into a hydrophobic cleft formed by helices α2 and α3 of the *Vc*HigA2 antitoxin. However, the observed ITC curves accompanying binding of the *Vc*HigA2~3-22~ peptide and the full-length antitoxin to the *Vc*HigB2 are very similar, suggesting that the major contributions to binding affinity come from the interaction between *Vc*HigA2 N-terminal domain and VcHigB2 while the interactions between the globular domains are less important ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"}). This is in line with our activity experiments that suggest that the first 20 amino acids from the disordered HigA2 N-terminus regulate the toxin activity.

Conformational changes of *Vc*HigB2 upon *Vc*HigA2 binding {#SEC3-7}
----------------------------------------------------------

Comparison of the conformations of *Vc*HigB2 in the nanobody complexes with the conformation observed in the *Vc*HigBA2 complex reveals two major differences: a displacement of the C-terminal helix α3 and a one-residue register shift in β-strand 3 (Figure [4C](#F4){ref-type="fig"}). The helix displacement is a direct consequence of the interaction with N-terminal helix of *Vc*HigA2, since both helices compete for an overlapping anchor site on the β-sheet surface (Figure [4C](#F4){ref-type="fig"}). In its novel position the α3 is rotated by ∼30°. The N-end roughly retains its original position, while the C-end is displaced by ∼13 Å compared to its position in the nanobody-bound *Vc*HigB2.

β-strand β3 consists of amino acid sequence 63-SRIIYYFL-70 and its central residues are part of the *Vc*HigB2 hydrophobic core. The electron density of this sequence is clear and allows unambiguous tracing of the polypeptide chain from the Arg60 or Gly62 in the in nanobody-*Vc*HigB2 structures (Figure [5A](#F5){ref-type="fig"}). Surprisingly, when this model is used to refine the structure of the *Vc*HigBA2 complex, clear difference peaks in mFo-DFc maps suggested an alternative tracing of the polypeptide (Figure [5B](#F5){ref-type="fig"}). A model with the amino acid sequence of β3 shifted by one residue (−1 shift in the β-strand register) clearly describes the data better (Figure [5C](#F5){ref-type="fig"}). Remarkably, this shifted conformation does not disrupt the hydrophobic packing interactions between β-sheet and the helices α1 and α2 of the *Vc*HigB2, because the four central hydrophobic residues are a repeat (65-IIYY-68), and therefore the positions of Ile65 and Tyr67 (in the Nb−*Vc*HigB2 complexes) are mimicked by Ile66 and Tyr68 in the *Vc*HigBA2 complex (Figure [5D](#F5){ref-type="fig"}). The shift in the β-strand register comes with a structural change likely crucial for the activity of the *Vc*HigB2 toxin. In the nanobody complexes Arg64, which is part of the active site, is oriented correctly relative to the other active site residues (in-conformation). In contrast, in the *Vc*HigBA2 complex the register shift flips this side chain to the opposite plane of the β-sheet (out-conformation) (Figures [4C](#F4){ref-type="fig"} and [5D](#F5){ref-type="fig"}). In the slided conformation the β3-β4 loop is one residue shorter, while β2-β3 loop is extended for one residue, but remains disordered in both conformations.

![Sliding of *Vc*HigB2 strand β3. (**A**) Model of the strand β3 from the Nb6-*Vc*HigB2 structure and the corresponding 2mFo-DFc map contoured at 1 σ (resolution 1.85 Å). (**B**) Positive (green) and negative (red) peaks in the mFo-DFc map contoured at 3 σ suggest a different tracing of the sequence of strand β3 in the *Vc*HigBA2 complex. (**C**) 2mFo-DFc and mFo-DFc maps (contoured at 1 σ and 3 σ, respectively; resolution 3 Å) for the final model of strand β3 in the *Vc*HigBA2 complex. (**D**) Schematic figure displaying strand β3 in both conformations. Unstructured β2-β3 loop is shown as dashed line, locations of the active site and solvent-inaccessible hydrophobic core are circled. Slided conformation (bottom) does not perturb the hydrophobic packing due to a sequence repeat.](gkx138fig5){#F5}

DISCUSSION {#SEC4}
==========

The *higBA* module on plasmid Rts1 was the first TA module discovered with an inverted gene organization, the toxin gene being located upstream of the antitoxin gene. Since then, the name '*higBA'* has been used for a plethora of TA modules where a toxin gene (weakly) related to *relE* is followed by an antitoxin gene that encodes a helix-turn-helix DNA binding motif. Our crystal structures show that the proteins encoded by the *V. cholerae* chromosomal *higBA2* module differ in significant aspects from those of the plasmid encoded Rts1 module ([@B17]) and that defining a distinct *higBA* family based solely on the gene order of toxin and antitoxin may be misleading. The toxin *Vc*HigB2 shows a much stronger similarity to the classic *E. coli* RelE both in terms of overall structure and in its atypical combination of the catalytic residues. The most striking difference between *Vc*HigB2 and *Ec*RelE is the sequence of loop β2-β3, which in *Vc*HigB2 is longer, rich in lysines and remains disordered. Substitution of this loop for a sequence of three alanines impairs toxin activity (Figure [1C](#F1){ref-type="fig"}). Superposition of *Vc*HigB2 on ribosome-bound *Ec*RelE (PDB ID: 4V7J, ([@B12])) suggests that this loop might form extensive interactions with the 16S RNA helices 18 and 34 (Figure [6A](#F6){ref-type="fig"}). *Ec*RelE interacts with the ribosomal RNA via two Lys and Arg-rich patches involving helices α1 and α2 ([@B12]). The same basic patches also mediate binding to the ribosomal A site in YoeB, YafQ and *Pv*HigB mRNAses ([@B13],[@B14],[@B54]). Surprisingly in *Vc*HigB2, helices α1 and α2 are not charged and superposition of *Vc*HigB2 on ribosome-bound *Ec*RelE shows minimal contacts between the ribosomal RNA and helices α1 and α2 of *Vc*HigB2 (only Lys13 from α1 seems to interact with 16S RNA helix 31). Given the absence of other contacts between the ribosome scaffold and the *Vc*HigB2 toxin, the positively charged β2-β3 loop likely mediates binding of the *Vc*HigB2 to the ribosomal A site by electrostatic interactions with the 16S RNA.

![Model of the *Vc*HigB2 toxin bound to the ribosome. The model was obtained by the superposition of the *Vc*HigB2 toxin on *Ec*RelE in the *Ec*RelE--ribosome complex (PDB ID: 4V7J). (**A**) *Vc*HigB2 positively charged β2-β3 loop (highlighted in yellow) interacts with helies 18 and 34 from the 16S RNA. The conformation of the β2-β3 loop was optimized using ModLoop web server ([@B61]). (**B**) *Vc*HigB2 toxin with bound *Vc*HigA2~3-33~ peptide placed in the *Vc*HigB2 binding site of ribosome using the *Ec*RelE--ribosome complex (PDB ID: 4V7J) as a guide. No obvious clashes are observed between the ribosome or the mRNA substrate and *Vc*HigB2 or *Vc*HigA2~3-33~.](gkx138fig6){#F6}

The relation between *V. cholerae higBA2* and *E. coli relBE* comes with an interesting switch in genetic organization. Not only does the Vc*higBA2* module have an inverted gene organization, the arrangement of the two functional domains of the *Vc*HigA2 antitoxin is inverted as well. The intrinsically disordered toxin-neutralizing domain is located N-terminal to the DNA binding domain, unlike in the *Ec*RelB as well as most other modular antitoxins ([@B55]). In stark contrast, *Pv*HigA lacks the toxin-binding intrinsically disordered domain and binds the toxin with the globular domain ([@B17]). The IDP domain of *Vc*HigA2 folds upon binding in an extended structure consisting of an α-helix followed by a β-strand. This motif is omnipresent in *relBE*-related TA modules (e.g. *dinJ-yafQ, yoeB-yefM*, ([@B55])) where this α-helix acts as the main regulatory element to control the activity of the toxin.

The inhibition of the ribosome-dependent mRNases such as *Vc*HigB, RelE, YoeB and YafQ by their cognate antitoxins, can be explained by the formation of large TA complexes, which cannot enter the ribosomal A site. Yet, in all cases the previously mentioned α-helical toxin-binding motif are sufficient to neutralize these toxins, often involving rearrangements in the active sites. For example, binding of the YefM C-terminal helix to YoeB induces a conformational rearrangement of the active site residues of the YeoB toxin ([@B15]). The C-terminal domain of DinJ directly covers the active site of the YafQ toxin ([@B19],[@B20]) and binding of *Ec*RelB displaces the C-terminal helix of *Ec*RelE, thereby distancing the catalytically important Tyr87 from the active site ([@B16]). Thus, in general short toxin-binding motifs act as minimal regulatory elements for the corresponding toxins and the perturbation of the active site is a general strategy for toxin inhibition. Indeed, our data show that the *Vc*HigA2 N-terminal domain containing the neutralization helix (peptide *Vc*HigA2~3-22~) is sufficient to neutralize *Vc*HigB2 (Figure [3A](#F3){ref-type="fig"}).

Like the C-terminal α-helix of *Ec*RelB, the N-terminal α-helix from *Vc*HigA2 displaces helix α3 of *Vc*HigB2. Displacement of α3 of *Vc*HigB2 does not perturb the active site of *Vc*HigB2 directly and in contrast to *Ec*RelE this helix does bear a catalytically important residue. Indeed the functional equivalent of Tyr87 located on helix α3 of *Ec*RelE is Tyr82 which is located on strand β4 of *Vc*HigB2 (Figure [1B](#F1){ref-type="fig"}). Even though there are no obvious large clashes between peptide-bound *Vc*HigB2 and the ribosome scaffold (Figure [6B](#F6){ref-type="fig"}) the *Vc*HigA2~3-22~ peptide prevents binding to the ribosome (Figure [3B](#F3){ref-type="fig"}).This may be explained by the observation of dynamic nature of the β3 strand. In the slided conformation the Arg64 can be found in or out of the active site due to the shift in the β-strand register (Figure [5D](#F5){ref-type="fig"}). Its structural homolog Arg61 from *Ec*RelE binds the mRNA molecule and has been identified as stabilizer of the negatively charged transition state ([@B51]). In all three nanbody-*Vc*HigB2 structures the Arg64 is found in the active in-conformation and interacts with the sulphate or phosphate ions from the crystallization solution (Figure [1A](#F1){ref-type="fig"}). On the other hand in the structure of the *Vc*HigBA2 complex, Arg64 is flipped to the other side of the β-strand and is no longer part of the active site and it cannot interact with mRNA molecule. Moreover, sliding of the β3 stand also extends the β2-β3 loop, which probably disrupts interactions with the ribosome (Figure [6B](#F6){ref-type="fig"}).

The sequence of strand β3 seems to acts as a 'chameleon' sequence and the *Vc*HigB2 exists in two conformations (active 'in' and non-active 'out'). This β-strand sliding toward the 'out' conformation would then need to be induced though the binding of the N-terminal helix of *Vc*HigA2. In addition, the interaction of VcHigB2 loop β2-β3 with the ribosome may help to stabilize the active 'in' conformation. Several examples of functional shifts in the β-strand registers have also been described in other proteins, for example during the signal transduction of the BLUF photoreceptor ([@B56],[@B57]) and in the Arf1 and Arl3 GTPases ([@B58],[@B59]), but the mechanism of β-strand sliding is poorly understood. This is the first observation of β-strand sliding in a ribonuclease and further research might clarify how the two conformations of *Vc*HigB2 are interconverted.
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